Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that on November 2, 2026, the Group and Lingke Pharmaceutical (Zhejiang) Co., Ltd. (Lingke Pharmaceutical) reached further cooperation on the selective JAK1 inhibitor zeprixitinib. The Group will receive exclusive commercial rights in mainland China, Hong Kong, Macao and Taiwan for moderate to severe atopic dermatitis (AD) and other dermatological indications in adults.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.